Oncotelic Therapeutics, Inc.
OTLC
$0.03
$0.001.00%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 247.50M | 247.38M | 249.28M | -1.67M | -3.93M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 419.00K | 304.80K | 198.10K | 140.60K | 100.90K |
| Total Other Non-Cash Items | -249.41M | -249.14M | -250.97M | 318.70K | 2.83M |
| Change in Net Operating Assets | -26.40K | -103.80K | 106.40K | 505.80K | 457.10K |
| Cash from Operations | -1.52M | -1.56M | -1.38M | -704.10K | -540.30K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 1.65M | 1.59M | 1.39M | 964.00K | 556.00K |
| Total Debt Repaid | 0.00 | -50.00K | -- | -- | -- |
| Issuance of Common Stock | 6.60K | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -33.00K | -- | -- | -- | -- |
| Cash from Financing | 1.62M | 1.54M | 1.39M | 964.00K | 556.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 98.10K | -15.50K | 2.70K | 259.90K | 15.70K |